 |
Hana Biosciences Obtains NASDAQ National Market Listing Approval
Apr 11, 2006
|
7.0 KB |
|
| |
South San Francisco, CA (April 11, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, received approval of its application to list its common shares on the NASDAQ National Market. Hana's common shares will begin trading on NASDAQ on Monday, April 17, 2006 under the symbol HNAB. The trading of H...
|
|
Hana Biosciences to Present at the Bio 2006 Business Forum
Apr 5, 2006
|
6.7 KB |
|
| |
South San Francisco, CA (April 5, 2006) – Hana Biosciences (AMEX: HBX) announced today that Fred Vitale, Vice President and Chief Business Officer, will present a company update at the BIO 2006 Business Forum on Tuesday, April 11, at 10:45AM CT in Room A, McCormick Place South, Level 3 Exhibit Hall A at The McCormick Place Convention Cente...
|
|
Hana Biosciences Initiates Talotrexin Phase II Clinical Trials in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Mar 31, 2006
|
11.1 KB |
|
| |
South San Francisco, CA (March 31, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, announced that the company initiated a multicenter, multinational Phase II clinical trial with Talotrexin (PT-523) in relapsed or refractory non-small cell lung cancer (NSCLC).
The primary objective...
|
|
Hana Biosciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference
Mar 31, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (March 31, 2006) – Hana Biosciences (AMEX: HBX) announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Tuesday, April 4, at 1:45PM ET in Room 3.05 at The Millennium Broadwa...
|
|
Hana Biosciences to Present at the Bear Sterns' Bear Biotech West Coast Confab
Mar 22, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (March 22, 2006) – Hana Biosciences (AMEX: HBX) announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Bear Biotech West Coast Confab on Thursday, March 23rd, at 12:30PM PT in the Terrace Room at The Fairmont Hotel in San Francisco.
A live audio web...
|
|
Hana Biosciences to License Three Targeted Cancer Drug Candidates from INEX Pharmaceuticals
Mar 17, 2006
|
53.1 KB |
|
| |
South San Francisco, CA (March 17, 2006) – Hana Biosciences (AMEX: HBX) signed a letter of intent to license the worldwide rights to develop and commercialize three novel targeted chemotherapy drug candidates for the treatment of solid and hematological cancers from Inex Pharmaceuticals Corporation (TSX: IEX). The three candidates are kno...
|
|
Hana Biosciences Reports 2005 Results from Operations
Mar 16, 2006
|
10.2 KB |
|
| |
South San Francisco, CA (March 16, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, reported its results of operations for 2005 and the filing of its annual report on Form 10-K.
Hana reported a net loss of $10.0 million, or $0.57 per share for the year ended December 31, 2005, com...
|
|
Hana Biosciences Successfully Completes Pivotal Trials of Zensana™, First Proprietary Ondansetron ORal Spray for Chemotherapy-Induced Nausea and Vomiting
Mar 9, 2006
|
9.7 KB |
|
| |
South San Francisco, CA (March 9, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, announced the successful completion of all clinical trials of Zensana™ (ondansetron oral spray) required for FDA registration under section 505(b)(2).
The Zensana™ clinical development ...
|
|
Hana Biosciences to Present at the Lehman Brothers 9th Annual Global Healthcare Conference
Mar 6, 2006
|
6.9 KB |
|
| |
South San Francisco, CA (March 6, 2006) – Hana Biosciences (AMEX: HBX) announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Lehman Brothers 9th Annual Global Healthcare Conference on Friday, March 10th, at 8:00 AM ET in Poinciana 4 at the Loews Miami Beach Hotel in South Beach, F...
|
|
Hana Biosciences to Present at Biosquare 2006
Mar 2, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (March 2, 2006) – Hana Biosciences (AMEX: HBX) announced today that Dr. Gregory Berk, Senior Vice President & Chief Medical Officer, will present at BioSquare 2006 in Geneva, Switzerland on Thursday, March 9th at 2:15 PM in Room 7 on the second level of the International Conference Centre Geneva – Switzerl...
|
|
Hana Biosciences to Present at the Cowen & Co. 26th Annual Health Care Conference
Feb 28, 2006
|
6.8 KB |
|
| |
South San Francisco, CA (February 28, 2006) – Hana Biosciences (AMEX: HBX) announced today that Mark Ahn, PhD, President & Chief Executive Officer, will present a company update at the Cowen & Co. 26th Annual Health Care Conference on Thursday, March 9th, at 8:50 AM ET in the Harvard Meeting Room on the 3rd floor at the Boston Mar...
|
|
Hana Biosciences Announces Issuance of Talotrexin Patent
Feb 14, 2006
|
7.6 KB |
|
| |
South San Francisco, CA (February 14, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, announced today the issuance of U.S. Patent No. 6,989,386 on January 24, 2006, from the U.S. Patent and Trademark Office. U.S. Patent No. 6,989,386 is directed to Talotrexin compositions and methods of ...
|
|
Hana Biosciences to Present at the 8th Annual Bio CEO & Investor Conference
Feb 7, 2006
|
6.9 KB |
|
| |
South San Francisco, CA (February 07, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, will present at the 8th Annual BIO CEO & Investor Conference, on Tuesday, February 14, 2006 at 3:00 PM EST. The presentation will take place in the Basildon Room at the Waldorf Astoria Hotel on 301 ...
|
|
Hana Bioscience Announces Positive Results of Initial Registration Trial with Zensana™, First Ondansetron Oral Spray for Chemotherapy-Induced Nausea and Vomiting
Jan 9, 2006
|
9.4 KB |
|
| |
South San Francisco, CA (January 9, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, announced the positive results of pivotal clinical trial ZOOS 1 (Zensana™ Ondansetron Oral Spray), a study which definitively demonstrated Zensana™ (ondansetron oral spray) 8 mg dose is bioequi...
|
|
Hana Biosciences Announces 2006 Corporate Goals
Jan 5, 2006
|
10.4 KB |
|
| |
South San Francisco, CA (January 5, 2006) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, today reviewed 2005 progress and announced its corporate objectives for 2006.
Key 2005 achievements and 2006 objectives for Hana include:
Q1 05: Pilot PK study in Zensana™ pil...
|
|
Hana Biosciences Announces Changes to Strengthen Management Team
Dec 16, 2005
|
10.0 KB |
|
| |
South San Francisco, CA (December 16, 2005) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, today announced management promotions and changes which will accelerate development of the company's pipeline and enable rapid commercialization of its first product, which is targeted for 2007 launch....
|
|
Hana Biosciences Reports Third Quarter Results
Dec 14, 2005
|
9.3 KB |
|
| |
South San Francisco, CA (December 14, 2005) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company that acquires, develops, and commercializes innovative products to advance cancer care, today reported its Third Quarter 2005 results. The company had a net loss of $1.71 million, or $0.09 per share for the quarter ended September 30, 20...
|
|
Hana Biosciences Initiates Pivotal Trials of Zensana™, First Ondansetron Oral Spray in Chemo-Induced Nausea and Vomiting
Dec 12, 2005
|
9.1 KB |
|
| |
South San Francisco, CA (December 12, 2005) – Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, announced today that the Food and Drug Administration has cleared its Investigational New Drug (IND) application for Zensana™. Hana is initiating today a series of pivotal pharmacokinetic trials, i...
|
|
Hana Biosciences to Present at the Bay Area Biotechnology and Healthcare Forum
Dec 5, 2005
|
6.6 KB |
|
| |
outh San Francisco, CA (December 5, 2005) – Hana Biosciences (AMEX: HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, will present at the Bay Area Biotechnology and Healthcare Forum, at 12:20 PM on December 7, 2005. The forum is being held at the Hyatt Regency San Francisco, 5 Embarcadero Center, S...
|
|
Hana Biosciences Announces Positive in Vivo Precinical Results Confirming Pharmacokinetics of Zensana™ (Ondansetron Oral Spray)
Nov 17, 2005
|
46.2 KB |
|
| |
South San Francisco, CA (November 17, 2005) – Hana Biosciences (AMEX: HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, announced positive data from a completed preclinical in vivo pharmacokinetic study comparing different formulations of Zensana™ (ondansetron oral spray) with commercially ...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds